Evaluating gain and loss-framed mobile messaging to improve maternal health service uptake: A cluster randomized controlled trial in Jimma, Ethiopia.

PLoS OneOct 26, 2026 (epub)

Gebeyehu Bulcha Duguma, Hordofa Gutema, Mulusew Gerbaba et al.

✦ AI-curated · Sources linked

In 30 seconds

This three-arm cluster-randomized controlled trial assessed whether gain- or loss-framed SMS messaging improved maternal health service use among 588 pregnant women in Jimma Zone, Ethiopia. Participants received 39 messages over 6–8 months or usual care. Compared with control, both messaging approaches increased attendance for antenatal care (ANC), skilled birth attendance (SBA), and postnatal care (PNC). The largest reported odds ratio was for ANC attendance with loss-framed messages (OR 7.14, 97.5% CI 2.40-21.26). Knowledge improved in both intervention groups, while self-efficacy did not change significantly.

Key findings

  • Gain-framed messaging increased ANC attendance (OR 5.40, 97.5% CI 1.95-14.94), SBA (OR 7.53, 97.5% CI 2.20-25.79), and PNC (OR 4.83, 97.5% CI 1.71-13.67) versus control.
  • Loss-framed messaging increased ANC attendance (OR 7.14, 97.5% CI 2.40-21.26), SBA (OR 7.31, 97.5% CI 2.13-25.09), and PNC (OR 4.07, 97.5% CI 1.46-11.39) versus control.
  • Knowledge improved in both messaging groups; attitudes improved only with gain-framed messages, and self-efficacy showed no significant change.
  • Self-reported maternal morbidity decreased in both intervention groups.

Why it matters

The trial suggests that mobile messaging can support uptake across several stages of maternal care in a rural, low-resource setting. Both message frames were associated with improved service use, while their reported effects differed across outcomes. These findings make message framing a potentially relevant consideration when designing maternal health communication, although the study does not establish which approach is preferable overall.

What to keep in mind

The trial was conducted in one zone of Ethiopia, and the abstract reports self-reported maternal morbidity. It does not provide enough information to assess the durability of effects beyond the study follow-up.

Source

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.